Macrophages are cells of the immune system that protect the host from invading pathogens. But in cancer, macrophages can be “hijacked” by tumors, and made to support their malignant growth and spread. This is a drawback for a major cancer treatment, immunotherapy, which turns the body’s immune system against the tumor. EPFL scientists, working with colleagues at the Roche Innovation Centers in Munich and Basel, have now identified a molecular “switch” that can convert the “hijacked” macrophages into cells that can stimulate the immune system to fight the growth and spread of cancer. The work is published in Nature Cell Biology.
Along with attacking foreign pathogens like bacteria, macrophages also help the body’s organs develop and its wounds heal. Their own behavior is fine-tuned by small molecules that they produce, called microRNAs.
When a tumor begins to develop, macrophages attempt to block its growth. But often tumors hijack them and convert them into what are known as “tumor-associated macrophages”, or TAMs for short.
Now corrupted, TAMs use their microRNAs to shield the tumor from the patient’s immune system, helping it grow and metastasize. This phenomenon is common across many tumor types. It is one of the major obstacles in treating cancer, and often leads to a poor prognosis for the patient.
Michele De Palma’s team at EPFL found how to reclaim TAMs. The researchers genetically modified TAMs to remove their ability to produce microRNAs. As a result, the TAMs were reprogrammed dramatically. Instead of protecting the tumor, the TAMs now signaled the presence of the tumor to the immune system, triggering attacks against it – and did so very efficiently.
Using a bioinformatics approach, the researchers found that the most likely culprit was a small family of microRNAs, called Let-7. This offers a more specific target: blocking Let-7 microRNAs may help instruct the TAMs to stimulate anti-tumor immunity.
Interestingly, the researchers observed that reprogramming TAMs also stops cancer cells from leaving the primary tumor. This could mean that the approach can also prevent tumor metastasis, the most threatening aspect of cancer. Moreover, the researchers found that the re-educated TAMs could enhance the anti-tumoral efficacy of certain cancer immunotherapies, some of which are already approved for patients.
However, more work is needed to translate all these findings to actual therapies, especially since there is currently no way to block the Let-7 microRNAs selectively in TAMs. But De Palma’s lab is now working with bioengineers at EPFL to design drugs that can target the Let-7 microRNAs specifically in the TAMs.
Some of the most promising cancer treatments are immunotherapies, which are based on provoking or enhancing the patient’s immune response against their tumor. “The most exciting finding was that TAM reprogramming greatly improved the efficacy of immunotherapy,” says Michele De Palma. “Our results in experimental models of cancer suggest a new therapeutic strategy based on inhibiting the microRNA machinery – or the Let-7 microRNAs – specifically in the TAMs, which may unleash the power of mainstream immunotherapies, such as immune checkpoint inhibitors”.
Learn more: Reclaiming the immune system’s assault on tumors
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- New report: Onco-Immunotherapy market research on December 28, 2018 at 3:03 am
Oncologists believe that Immunotherapy could be that wonder therapy for cancer. Since 2016, this innovation shifted the way in which cancer is treated and has transformed care for many patients. Immun... […]
- MSI Status in Prostate Ca Could ID Immunotherapy Responders on December 27, 2018 at 11:58 am
Although rare overall, about half of patients with prostate cancer with a specific determinant of immunotherapy response -- microsatellite instability (MSI)-high/mismatch repair-deficient (dMMR) pheno... […]
- Immunotherapy Advances SCLC Treatment Landscape on December 27, 2018 at 11:43 am
The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer (SCLC) should be atezolizumab (Tecentriq) and chemotherapy, based on results from the IMpow... […]
- Classes of Immunotherapy Under Investigation in Multiple Myeloma on December 27, 2018 at 6:50 am
In 2017, the FDA halted trials examining checkpoint inhibitors in multiple myeloma due to excess toxicity, which left an unclear role for this class of agents in this disease. Now, there are 3 classes ... […]
- Cancer immunotherapy biotech Harpoon Therapeutics files for a $86 million IPO on December 27, 2018 at 12:31 am
Harpoon Therapeutics, a Phase 1 biotech developing immunotherapies for various cancers, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The South San Francisco ... […]
- Pruritis Can Be Frequent, Severe With Cancer Immunotherapy on December 24, 2018 at 10:20 am
Pruritus is a not uncommon adverse event in patients receiving any type of immunotherapy for the treatment of cancer and can significantly compromise quality of life and overall function in those most ... […]
- Yale Cancer Center scientists advise caution in immunotherapy research on December 20, 2018 at 12:47 pm
In a new study by Yale Cancer Center (YCC), scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to bet... […]
- Sell-Side Slashes DBV Tech Price Targets After Withdrawal Of BLA For Peanut Allergy Immunotherapy on December 20, 2018 at 10:14 am
DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) shares were losing more than half of their value in Thursday trading following an update on the company's lead pipeline candidate. What Happened DBV said ... […]
- Scientists advise caution in immunotherapy research on December 20, 2018 at 8:02 am
In a new study, Yale Cancer Center (YCC) scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to ... […]
- Baltimore immunotherapy company opens Philadelphia office on December 20, 2018 at 4:00 am
WindMil Therapeutics, a clinical-stage cancer immunotherapy company based in Baltimore, has opened a Philadelphia office to accommodate its expanding executive, operations and clinical teams. The comp... […]
via Bing News